Boston Scientific (BSX) is expected to report its third-quarter of fiscal 2018 earnings on October 24. In this series, we’ll look at Boston Scientific’s expected top-line, operational, and bottom-line performances for the third quarter of 2018. We’ll also look at analysts’ recommendations and the performance of Boston Scientific stock so far this year.
The company mainly generates revenues from the sale of single-use medical devices and operates in three business segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The MedSurg segment includes its endoscopy and urology and pelvic health businesses. The Rhythm and Neuro segment includes its cardiac rhythm management, electrophysiology, and neuromodulation businesses. The cardiovascular segment includes its interventional cardiology and the peripheral interventions businesses.
On October 16, Boston Scientific announced the closure of the acquisition of Augmenix. The latter has developed and brought to market SpaceOAR Hydrogel System to reduce the side effects of radiotherapy to treat prostate cancer.
Analysts expect Boston Scientific’s revenues to increase by 8.17% from $2.22 billion in the third quarter of fiscal 2017 to $2.40 billion in the third quarter of fiscal 2018. In the third quarter of fiscal 2017, its revenues rose 5.56%. Over the last four quarters, its revenue growth has ranged between 5.6% and 10.32%.
For fiscal 2018 and 2019, Boston Scientific is expected to generate revenues of $9.85 billion and $10.59 billion, respectively. In fiscal 2017, Boston Scientific had generated revenues of $9.05 billion.
We’ll take a look at Boston Scientific’s expected operational performance for the third quarter of fiscal 2018 in the next part.